ArticleFrontiers in medicine2026
A combined model of BCVA, TRAb, and NLR predicts response to intravenous methylprednisolone in dysthyroid optic neuropathy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-dose intravenous methylprednisolone (HD-IVMP) is the first-line treatment for dysthyroid optic neuropathy (DON). However, a significant proportion of patients exhibit a poor response, risking irreversible vision loss when surgical decompression is delayed. Identifying reliable predictors for failure of HD-IVMP is crucial for optimizing treatment strategies. This retrospective study aimed to identify risk factors associated with a poor response to HD-IVMP in DON patients, develop a predictive model for clinical decision-making, and assist in determining the optimal timing of orbital decompression surgery. Methods: A retrospective cohort study was conducted involving 44 patients (44 eyes) diagnosed with DON and treated with HD-IVMP. Basic characteristics, clinical features, orbital computed tomography (CT) findings, and laboratory parameters were analyzed. Treatment response was defined as complete visual recovery without requiring surgical decompression within 6 months. Least absolute shrinkage and selection operator (LASSO) and multivariable logistic regression analyses were used to screen and identify independent predictive factors. The predictive performance of the model was evaluated by plotting the receiver operating characteristic (ROC) curve. Additionally, decision curve analysis (DCA), net reclassification index (NRI), integrated discrimination improvement (IDI), and bootstrap internal validation were used to evaluate the clinical utility of the model. Results: At the 6-month follow-up, 20 of the 44 (42.5%) eyes achieved complete visual recovery and consequently avoided surgical decompression. A multivariable analysis identified three independent predictors of non-response to HD-IVMP: poorer baseline best-corrected visual acuity (BCVA; odds ratio [OR] = 1.43, 95% CI: 1.05-1.95, Conclusion: This study establishes that baseline BCVA, TRAb, and NLR are significant and readily available risk factors for failure of HD-IVMP in DON. The developed combination model provides clinicians with a valuable tool for the early identification of patients who are unlikely to benefit from medical therapy alone, thereby facilitating timely surgical intervention to prevent permanent visual damage and improve overall management outcomes. External validation of this model is required in future prospective studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.